Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (181-190 of 272) with videos related to

Pageof 28
Sort By:
The Journal of Rheumatology|November 15, 2022
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV TrialFilip Van den Bosch, James Cheng-Chung Wei, Peter Nash, et al.
RMD Open|December 20, 2018
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studiesJürgen Braun, Atul Deodhar, Robert Landewé, et al.
Rheumatology (Oxford, England)|August 12, 2024
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatmentAtul Deodhar, Alan J Kivitz, Marina Magrey, et al.
The Journal of Rheumatology|May 1, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
RMD Open|March 17, 2022
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd studyDésirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, et al.
Arthritis Care & Research|August 18, 2019
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II TrialPhilip S Helliwell, Atul Deodhar, Alice B Gottlieb, et al.
ACR Open Rheumatology|February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 StudyChristopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
RMD Open|July 21, 2022
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trialPhilip S Helliwell, Phillip J Mease, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|April 8, 2020
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging studyDésirée van der Heijde, Lianne S Gensler, Atul Deodhar, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW studyIrene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, et al.
Pageof 28

Showing results (181-190 of 272) with videos related to

Sort By:
Pageof 28
The Journal of Rheumatology|November 15, 2022
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV TrialFilip Van den Bosch, James Cheng-Chung Wei, Peter Nash, et al.
RMD Open|December 20, 2018
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studiesJürgen Braun, Atul Deodhar, Robert Landewé, et al.
Rheumatology (Oxford, England)|August 12, 2024
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatmentAtul Deodhar, Alan J Kivitz, Marina Magrey, et al.
The Journal of Rheumatology|May 1, 2023
Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST ProgramAtul Deodhar, Denis Poddubnyy, Proton Rahman, et al.
RMD Open|March 17, 2022
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd studyDésirée van der Heijde, Lianne S Gensler, Walter P Maksymowych, et al.
Arthritis Care & Research|August 18, 2019
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II TrialPhilip S Helliwell, Atul Deodhar, Alice B Gottlieb, et al.
ACR Open Rheumatology|February 10, 2023
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 StudyChristopher T Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, et al.
RMD Open|July 21, 2022
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trialPhilip S Helliwell, Phillip J Mease, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|April 8, 2020
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging studyDésirée van der Heijde, Lianne S Gensler, Atul Deodhar, et al.
Therapeutic Advances in Musculoskeletal Disease|April 15, 2021
Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW studyIrene E van der Horst-Bruinsma, Rianne E van Bentum, Frank D Verbraak, et al.
Pageof 28